



Company Name: Linical Co., Ltd.
Representative: Kazuhiro Hatano
President & CEO
(TSE code: 2183)

18th September 2020

New Award of Clinical Trial for New COVID-19 Treatment

Linical Co., Ltd. (Head Office address: Yodogawa-ku, Osaka City, hereafter "Linical") has entered into a service contract with The Kitasato Institute (Address: Shirokane, Minato-ku, Tokyo, hereafter "Kitasato"¹) regarding an investigator-initiated clinical trial for a new indication of ivermectin² against the COVID-19 on September 9th, 2020.

Linical will contribute to the health of patients, by applying Risk-Based Monitoring in this clinical trial, collecting highly reliable data contributing to the rapid and reliable development of this new indication.

The below is the related press release by Kitasato:

(September 17, 2020; Kitasato Institute, "Initiation of an investigator-initiated clinical trial of Ivermectin against COVID-19.")

<https://www.kitasato.ac.jp/jp/news/20200917-02.html>)

<References>

1: The Kitasato Institute

Established by Dr. Shibasaburo Kitasato in 1914, whose management philosophy is "With profound respect for the sanctity of life, our purpose is to contribute to society by dedicating ourselves to the quest for truth through the application of practical science." The institute's mission is to return the accumulated wisdom of life science, which has been developed over a century since its establishment, to society.

2: Ivermectin

Macrolide antibiotic discovered by Dr. Satoshi Ōmura, Distinguished Emeritus Professor of Kitasato University, who was awarded the 2015 Nobel Prize in Physiology or Medicine.

In addition to being used as a veterinary drug for parasite control, it is also used to treat several types of parasite infestations, such as onchocerciasis (river blindness) and lymphatic filariasis. In 2019, approximately 400 million people, mainly in Africa, Central and South America, were treated with this medication.

END